By David Hanson MP / Latest News / 0 Comments

Calling for better support for women with ovarian cancer

I have shown my support for women with ovarian cancer across Delyn by joining Target Ovarian Cancer at the launch of their state-of-the-nation Pathfinder study on 23 November in parliament.

Women with ovarian cancer are left stranded without vital support at every turn, from diagnostic tests to access to nurses, according to Pathfinder.

Pathfinder 2016 found that:
• Just one in five UK women (20 per cent) could name bloating as a major symptom of ovarian cancer, an alarmingly low rate of awareness.
• Almost half of women (41 per cent) visited their GP three times or more before being referred for ovarian cancer tests, risking a delayed diagnosis.
• Less than half of cancer nurses (46 per cent) think that their cancer unit has enough nurses to care for all the women being treated there.

Ovarian cancer is the deadliest of all the gynaecological cancers, with 15 per cent of women dying within two months of being diagnosed, and only a third of women surviving 10 years after their diagnosis.

Now Target Ovarian Cancer and women with ovarian cancer across the UK are calling on government and health bodies to improve services and invest to secure the futures of women with ovarian cancer today and those diagnosed tomorrow.

I’m really pleased to be here to ensure that all women with ovarian cancer get the care, support and new treatments that are needed, so that women’s lives are transformed, now and in future.

Annwen Jones, Chief Executive of Target Ovarian Cancer, said: “Women with ovarian cancer are being failed at diagnosis, in access to trials and effective drugs, and they lack support. They deserve better than this. Over 100 MPs and healthcare professionals attended our event today, and we called on each one of them to commit to invest in ovarian cancer today, to save lives tomorrow.”

Ovarian cancer can be devastating. Every year 7,300 women are diagnosed with ovarian cancer in the UK, and 4,100 women die from the disease.

Pathfinder 2016 is the most-comprehensive study of its kind into the lives of people living and working with ovarian cancer in the UK. It surveyed women in the general population, women with ovarian cancer, GPs, nurses, friends and family to provide a comprehensive assessment of how lives can be saved and improvements made. Pathfinder launches in parliament on 23 November. To find out more, visit www.targetovariancancer.org.uk/Pathfinder2016